Growth Strategies Case Study

Merck In 2003

OR

Abstract:
In 1990s, Merck had a double-digit profit growth rate. Since 2001 its growth fell to single-digit as competitors merged and forged ahead. Analysts have predicted an earnings growth rate of just 2% for Merck against 8% to 10% for the industry between 2001 and 2006. In the face of a weak R&D pipeline and the loss of patent protection of several key products, Merck's pipeline for new drugs is poor when compared with its other counterparts. In this scenario will the company consider merging with other companies to improve its R&D pipeline, save costs and boost growth and thereby win the trust of its investors?

Pedagogical Objectives:

• To highlight Merck's future R&D prospects
• To discuss the strategic options for the company to regain its lost momentum.

Keywords : Merck & Co. Inc; Research and development; Growth Strategies Case Study; Blockbusters; United States pharmaceutical industry; GlaxoSmithKline Novartis Pfizer, Inc; Vioxx Cozaar Hyzaar; Big pharma companies; Mergers and acquisitions; New molecular entities; United States Food and Drug Administration; New drug application; Generic competition; Schering-Plough; Zocor Zetia

Contents : 
Introduction
Background
Merck’s R&D Pipeline
Merck’s Financial Highlights